Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year.

What is Bladder Cancer?

Bladder cancer refers to the growth of a tumor within the lining of the bladder. In some cases, the tumor can invade surrounding tissue and spread to other parts of the body.

What Causes Bladder Cancer?

Bladder Cancer Diagnosis

Bladder Cancer Treatment

Bladder Cancer Types

Symptoms of Bladder Cancer

What is Intravesical Therapy?

Bladder Cancer Biomarkers

Bladder Cancer Histopathology

Endoscopic Imaging for Bladder Cancer

Thromboembolism in Bladder Cancer

Non-Invasive Diagnostic Strategies for Bladder Cancer

See more featured articles »

Bladder Cancer Genomics

Bladder Cancer Risk Factors

Muscle Invasive Bladder Cancer (MIBC)

Muscle Invasive Bladder Cancer (MIBC) Diagnosis and Treatment

Latest Bladder Cancer News and Research

E.coli toxin-producing bacteria linked to bladder and bowel cancer

Certain intestinal bacteria are found more frequently in countries such as Norway than in a number of other countries and there is also a higher incidence of bladder cancer, bowel cancer and prostate cancer.

6 Dec 2024

Advances in bladder cancer treatments offer hope for curative care

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in the New England Journal of Medicine.

14 Nov 2024

New treatment combination improves outcomes for small cell bladder and prostate cancer patients

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

12 Nov 2024

Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

9 Nov 2024

Study highlights long-term risks of prostate cancer treatment

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after treatment ends.

7 Nov 2024

Urine transcriptomics: A new frontier for non-invasive genitourinary disease detection

Researchers explore the potential diagnostic utility of transcriptomic and metabolic signals in the genitourinary system.

29 Oct 2024

Tiny magnetic soft robots pave the way for targeted drug delivery

A team of scientists at Nanyang Technological University, Singapore (NTU Singapore) has developed grain-sized soft robots that can be controlled using magnetic fields for targeted drug delivery, paving the way to possible improved therapies in future.

25 Oct 2024

New drug TYRA-300 shows effectiveness in treating metastatic bladder cancer

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

24 Oct 2024

Mini-protein AKY-1189 delivers targeted radiation to tumor cells

Researchers have shown for the first time that it is possible for a specially-designed 'mini-protein' to deliver a radiation dose directly to tumour cells expressing a protein on their cell surfaces called Nectin-4, which is often found in a number of different cancers.

24 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

Study illuminates the origin and progression of bladder cancer

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center.

9 Oct 2024

Research shows link between multiple sclerosis to increased risk of certain cancers

A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS.

9 Oct 2024

Early blood test can predict treatment response and survival prospects in metastatic prostate cancer

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.

7 Oct 2024

SWOG S1011 trial questions the benefits of extended lymphadenectomy in bladder cancer

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days after surgery.

3 Oct 2024

UTA cancer researcher elected president of the American Society for Photobiology

University of Texas at Arlington cancer researcher Sherri McFarland has been elected president of the American Society for Photobiology (ASP), a national scientific organization dedicated promoting research related to the effects of light on human health and the broader natural world.

20 Sep 2024